![AstraZeneca Partnership Gives Significant Boost To Sun Pharma's Overall China Entry Strategy, Says GlobalData AstraZeneca Partnership Gives Significant Boost To Sun Pharma's Overall China Entry Strategy, Says GlobalData](https://vertassets.blob.core.windows.net/image/bf1cf25e/bf1cf25e-23e8-4921-80d0-434efc8960c7/pr7318.png)
AstraZeneca Partnership Gives Significant Boost To Sun Pharma's Overall China Entry Strategy, Says GlobalData
CHINA MEDICAL SYSTEM HOLDINGS LIMITED 康哲藥業控股有限公司 * (Incorporated in the Cayman Islands with limited liabil
A +60M€ REGIONAL DEVELOPMENT AND COMMERCIALISATION AGREEMENT SIGNED WITH CHINA MEDICAL SYSTEM HOLDING LIMITED® Paris, July 3
![China Medical System Holdings Ltd.: China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro China Medical System Holdings Ltd.: China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro](https://www.finanznachrichten.de/chart-china-medical-system-holdings-ltd-aktie-intraklein-stuttgart.png)
China Medical System Holdings Ltd.: China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro
![China Medical System received MSCI-ESG “AA” rating again, leading the industry in ESG management – CMS China Medical System received MSCI-ESG “AA” rating again, leading the industry in ESG management – CMS](https://web.cms.net.cn/wp-content/uploads/2023/07/%E4%B8%80%E8%B5%B7-1.png)
China Medical System received MSCI-ESG “AA” rating again, leading the industry in ESG management – CMS
Sun Pharma gives licence to CMS for commercialization of 7 generic products in China, ET HealthWorld
![Chinese Healthcare Investors - Private Equity, Venture Capital and Family Office Investor from China Chinese Healthcare Investors - Private Equity, Venture Capital and Family Office Investor from China](https://www.sinabeat.com/images4/china-uk-ther.png)
Chinese Healthcare Investors - Private Equity, Venture Capital and Family Office Investor from China
China Medical System Holdings Limited annonce l'approbation d'un essai clinique de phase 3 portant sur la crème Ruxolitinib dans le traitement du vitiligo en Chine -Le 12 décembre 2023 à 14:28 | Zonebourse
![China Medical System Holdings Limited: Aktionäre Vorstände Geschäftsführer und Unternehmensprofil | A1JLYP | KYG211081248 | MarketScreener China Medical System Holdings Limited: Aktionäre Vorstände Geschäftsführer und Unternehmensprofil | A1JLYP | KYG211081248 | MarketScreener](https://de.marketscreener.com/static/address/6727703.png)